ArticleFrontiers in oncology2022
Radiomics of dynamic contrast-enhanced magnetic resonance imaging parametric maps and apparent diffusion coefficient maps to predict Ki-67 status in breast cancer.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Clinically Robust Deep Learning for Contrast-Enhanced Mammography: Multicenter Evaluation Across Convolutional Neural Network Architectures.Bioengineering (Basel, Switzerland) · 2026Article
- Engineering the Image Representation for Deep Learning in Contrast-Enhanced Mammography: A Systematic Analysis of Preprocessing and Anatomical Masking.Bioengineering (Basel, Switzerland) · 2026Article
- Predicting breast cancer response to neoadjuvant therapy by integrating radiomic and deep-learning features from early-and-peak phases of DCE-MRI.BMC cancer · 2025Article
- Perioperative Immune Checkpoint Inhibitors for the Treatment of Locally Advanced Gastric and Gastroesophageal Junction Cancer: Current Status and Future Prospects.Current treatment options in oncology · 2025Review
- Machine and Deep Learning on Radiomic Features from Contrast-Enhanced Mammography and Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Breast Cancer Characterization.Bioengineering (Basel, Switzerland) · 2025Article
- PET/CT Radiomics Integrated with Clinical Indexes as a Tool to Predict Ki67 in Breast Cancer: a Pilot Study.Nuclear medicine and molecular imaging · 2025Article
- Interpretable model based on MRI radiomics to predict the expression of Ki-67 in breast cancer.Scientific reports · 2025Article
- An Informative Review of Radiomics Studies on Cancer Imaging: The Main Findings, Challenges and Limitations of the Methodologies.Current oncology (Toronto, Ont.) · 2024Review
- Radiomics and artificial intelligence analysis by T2-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging to predict Breast Cancer Histological Outcome.La Radiologia medica · 2023Article
- Rutin Promotes Proliferation and Orchestrates Epithelial-Mesenchymal Transition and Angiogenesis in MCF-7 and MDA-MB-231 Breast Cancer Cells.Nutrients · 2023Article
- Development of an interpretable machine learning model for Ki-67 prediction in breast cancer using intratumoral and peritumoral ultrasound radiomics features.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study was aimed at evaluating whether a radiomics model based on the entire tumor region from breast dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) parametric maps and apparent diffusion coefficient (ADC) maps could indicate the Ki-67 status of patients with breast cancer. Materials and methods: This retrospective study enrolled 205 women with breast cancer who underwent clinicopathological examination. Among them, 93 (45%) had a low Ki-67 amplification index (Ki-67 positivity< 14%), and 112 (55%) had a high Ki-67 amplification index (Ki-67 positivity ≥ 14%). Radiomics features were extracted from three DCE-MRI parametric maps and ADC maps calculated from two different b values of diffusion-weighted imaging sequences. The patients were randomly divided into a training set (70% of patients) and a validation set (30% of patients). After feature selection, we trained six support vector machine classifiers by combining different parameter maps and used 10-fold cross-validation to predict the expression level of Ki-67. The performance of six classifiers was evaluated with receiver operating characteristic (ROC) analysis, sensitivity, and specificity in both cohorts. Results: Among the six classifiers constructed, a radiomics feature set combining three DCE-MRI parametric maps and ADC maps yielded an area under the ROC curve (AUC) of 0.839 (95% confidence interval [CI], 0.768-0.895) within the training set and 0.795 (95% CI, 0.674-0.887) within the independent validation set. Additionally, the AUC value, compared with that for a single parameter map, was moderately increased by combining features from the three parametric maps. Conclusions: Radiomics features derived from the DCE-MRI parametric maps and ADC maps have the potential to serve as imaging biomarkers to determine Ki-67 status in patients with breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.